Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

30-08-2016(Tue) 29-08-2016(Mon) 26-08-2016(Fri) 25-08-2016(Thu) 24-08-2016(Wed)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
30 Aug, 2016 (Tuesday)

BOC Aviation (2588) has announced the interim results for the six months ended 30 June 2016. Total revenues and other income rose 8.2% to US$579 million. Net profit after tax was US$212 million, an increase of 23.8% over the first half of 2015. At 30 June 2016, its fleet comprised 265 owned and managed aircraft on lease to 64 customers in 31 countries with an average remaining lease term of 7.2 years. The Group had commitments to acquire 218 aircraft through to 2021, averaging 40 aircraft a year over the period from 2016 to 2021.
Recommended Buy Price : HK$38; Target Price : HK$42; Stop Loss : HK$36

HEC Pharm (1558-HK) recently made a positive announcement. It is estimated that the company will see a no lower than 35% growth in net profit in the first half of the year mainly due to a surge of sales volume of the flagship product Oseltamivir Phosphate (Kewei) and the continuing improvement of marketing and promoting ability of the company on professional academics. HEC Pharm is currently the only licensed company to produce and sell active pharmaceutical ingredients (API), granules and capsules of Oseltamivir. Specifically, Oseltamivir Phosphate Granules is the exclusive product in Chinese pediatric drug market. This exclusive license has made the company the leading enterprise in selling Oseltamivir since 2013. We maintain a positive attitude towards the growth of Kewei, expecting it to be a one-billion class brand. The research team of HEC consists of 1200 researchers, including 4 experts from the Thousand Talents Program of China. Therefore, the R&D system is outside the company but good brands could be brought in the listed company and provide support to the medium and long term development.
Buy-in Price: $17.7, target Price: $20, Cut Loss Price: $16.6

KPC Pharmaceuticals (600422.CH) - Rapid Growth Still Expectable

1H16 Performance Worse than Expectation

In the first half of 2016, KPC Pharmaceuticals obtained RMB2.5 billion of revenue and RMB225 million of net profit after deduction of non-recurring gain/loss attributable to the shareholders, with an increase of 14.23% and 13.98% YOY, but lower than estimates.

Improved Performance of KPC Pharm

Source: Company reports, Phillip Securities (HK) Research

Specifically, the Company achieved a steady growth of 12% for its Xuesaitong series. The sales of Xuesaitong Soft Capsules rose rapidly. The Xuesaitong Injection had practically safe and reliable curative effects. Its standardization was approved as a key national project, we believe it can gain a greater market share under the background of restricted use of TCM injections. Moreover, the revenue from synthetic drugs amounted to RMB274 million with an increase of 10.45%. The pharmaceutical business revenue jumped by 20.67%, mainly thanks to financial support and fine management.

Regarding profitability, the gross profit margin reached 37.8% with a year-on-year increase of 1.5 percentage points, which mainly resulted from the gross profit margin of botanical drugs elevated by 9.6 percentage points to 74.5% as well as the drug wholesale and retail gross profit margin raised by 0.2 percentage points. However, the corporate marketing channels penetrated into the grassroots and the market promotion expenses increased, so the marketing expense ratio also rose by about 2 percentage points to 20.7%. As a result, the net profit margin dropped by 0.5 percentage points to 10%.

Improved earning capabilities

Source: Company reports, Phillip Securities (HK) Research

Rapid Growth Still Expectable

During the past ten years, the operating results of the company have basically maintained a high growth rate of over 20%, except in 2008 and 2014 when the growth rate went below 20%. Though the result was not as good as expected in 1H16, we keep optimistic about the mid- and long-term development of the company.

Firstly, the company has continuously pushed forward its refined marketing reform, set up new business departments like OTC, increased investment in the marketing business line integration and channel penetration, and strengthened incentives for frontline personnel. The Company's marketing advantages are expected to be intensified.

Secondly, upon the changes in the controllers of Zhongheng Group, the core product Xuesaitong Injection of KPC Pharmaceuticals may face the competition pattern reconstruction and its sales can increase steadily each year of 5-10% in the mid-term. While its exclusive products Xuesaitong Soft Capsules are estimated to embrace a high growth rate of around 30% exactly by virtue of the dramatically strengthened safety of oral preparations.

Furthermore, Tianxuanqing series are primarily used for neurological diseases with remarkable competitive advantages. Gastrodin Injection features high quality and competitive price. Acetagastrodin Tablets are exclusively owned by the Company. Besides, the Company plans to release "Liver-Soothing Granules and Xiangsha Pingwei Granules" as the golden prescription drugs and "Banlan Qingre Granules, Shenling Jianpiwei Granules, and Qingfei Huatan Pills" as the golden OTC drugs. Resources will be pooled to make a breakthrough in the sales volume of these five golden products and further drive the speedy increase in the botanical drug series.

What is also worth mentioning is that the expense ratio was relatively high and the conformance assessment expense was not capitalized in 1H16, so the growth rate of operating result is expected to remain above 20% if such expense is capitalized at the end of the year.

Further Expansion of Medical Service Businesses

KPC Pharmaceuticals is actively building a management ecosystem centered on cardio-cerebral-vascular diseases and other chronic diseases. It engages in the O2O diagnosis and treatment of cardio-cerebral-vascular diseases by investing the "Orange Doctor". Recently, it also cooperatively establishes the rehabilitation hospital and expands medical service businesses on the platform of Nanjing Hongjing and based on the operation of pharmaceutical business. It adopts the model of uniting pharmaceutical enterprises, agents and hospitals, which can be quickly copied into chain operation of rehabilitation service in the future. There is also a chance that the Company will actualize a series of mergers and acquisitions across Yunnan Province in the future, which can promote the chronic disease management business continually.


In general, there is still large space for the development of the Company's Kunming traditional Chinese medicines and Xuesaitong Soft Capsules, etc. Concurrently, the Company focuses on creating the chronic disease management system, speeds up its medical business layout and shows a strong intention to engage in epitaxial mergers. We give an estimation of 27.2x EPS in 2016 with the target price of RMB18.18, with the "Buy" rating maintained. (Closing price at 25 Aug 2016)

Historical P/E valuation

Source: Bloomberg, Phillip Securities (HK) Research


The rising prices of traditional Chinese medicinal materials;The drug development progress slower than expectation;The progress for extensions falls short of expectation.


Source: Company, Phillip Securities (HK) Research Estimates(Financial figures as at 25 Aug 2016)

Click Here for PDF format...

Writer Info
Fan Guohe
(Research Analyst)
Tel: (86 21 51699400-110)

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Stock Borrowing & Lending

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong ½÷¥ß¬ã¨s³¡ ¡V ­»´ä¤Î¤¤°ê
Company Stock Code Last Update Suggestion Target Price Price on Recom
Transportation and Automobiles Zhang Jing (86)
Insurance Research Department (86) 21
Media & Publishing Research Department (+ 86 21 51699400-107)
Wisdom Sports Group166111/07/2016Buy3.32.18
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)
KPC Pharmaceuticals 60042230/08/201618.180.000
Jumpcan Pharma60056619/08/2016Accumulate34.328.97
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)
Shanghai Haohai Biological Technology682606/06/2016Buy48.1839.55
Hengrui Medicine60027610/05/2016BUY56.546.92
New Energy Research Department (86) 21
Yunnan Water683923/05/2016Buy5.73.94
Grandblue ENV60032320/04/2016Buy 17.513.11
Food, Beverage and Retail Research Department (86) 21
361 Degrees136126/08/2016Buy3.22.48
Poly Culture363625/08/2016Accumulate23.519.84
Telecommunications Fan Guohe + (86) 21
Byaa Interactive43405/07/2016Accumulate32.71
Kingsoft Corporation Limited388828/06/2016Buy19.114.86
Mainland Property Research Department (86) 21
Fortune REIT77823/08/2016No Rating9.65
Fortune REIT77822/08/2016No Rating9.65
Utilities Research Department (86) 21
Jingneng Clean Energy57912/08/2016Buy3.22.44
Canvest Environmental Protection Group Co., Ltd.138121/07/2016Buy 4.73.4
Software & Service Research Department (86) 21
Goldpac Group331518/02/2015N/A4.77
Hotels and Entertainment Zhang Jing (+ 86 51699400-103)
Jinjiang Hotels200608/07/2016Accumulate2.982.49

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2016 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]